All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During SOHO 2019 in Houston, US, the Lymphoma Hub was pleased to speak with Prof. Philippe Gaulard from Hôpital Henri Mondor, Paris, FR, about the current understanding of the pathogenesis of T-cell lymphoma. He discusses different subtypes of the disease, their underlying biology including mutations, and how we can target them using existent therapies.
How do we currently understand the pathogenesis of T-cell lymphoma?
How should patients with T-cell lymphoma be treated in 2019?
During SOHO 2019 in Houston, US, the Lymphoma Hub was pleased to speak to Dr Julie Vose about optimal treatment regimen for patients with T-cell lymphoma in 2019
Alemtuzumab and CHOP for aggressive T-cell lymphoma
In this phase I, dose escalation trial, the authors investigated the possibility of combining CHOP chemotherapy with alemtuzumab, as a potential regimen against aggressive T-cell lymphoma.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox